Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11145615 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Adi S, Wu NY, Rosenthal SM (2001) Growth factor-stimulated phosphorylation of Akt and p70(S6K) is differentially inhibited by LY294002 and Wortmannin. Endocrinology 142, 498-501 11145615
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T444-p - p70S6K (human) ▲
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): ‑
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  C2C12 (myoblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
LY294002 IGF-1 inhibit treatment-induced increase
wortmannin IGF-1 inhibit treatment-induced increase
insulin increase
LY294002 insulin inhibit treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
PDGF increase
LY294002 PDGF inhibit treatment-induced increase
wortmannin PDGF inhibit treatment-induced increase

S447-p - p70S6K (human) ▲
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): ‑
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  C2C12 (myoblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
LY294002 IGF-1 inhibit treatment-induced increase
wortmannin IGF-1 inhibit treatment-induced increase
insulin increase
LY294002 insulin inhibit treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
PDGF increase
LY294002 PDGF inhibit treatment-induced increase
wortmannin PDGF inhibit treatment-induced increase

S473-p - Akt1 (mouse) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  C2C12 (myoblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
LY294002 IGF-1 inhibit treatment-induced increase
wortmannin IGF-1 inhibit treatment-induced increase
insulin increase
LY294002 insulin inhibit treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
PDGF increase
LY294002 PDGF inhibit treatment-induced increase
wortmannin PDGF inhibit treatment-induced increase

S473-p - Akt1 (rat) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  L6E9
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
LY294002 IGF-1 inhibit treatment-induced increase
wortmannin IGF-1 inhibit treatment-induced increase
insulin increase
LY294002 insulin inhibit treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
PDGF increase
LY294002 PDGF inhibit treatment-induced increase
wortmannin PDGF inhibit treatment-induced increase

T444-p - p70S6K (rat) ▲
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): ‑
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  L6E9
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
LY294002 IGF-1 inhibit treatment-induced increase
wortmannin IGF-1 inhibit treatment-induced increase
insulin increase
LY294002 insulin inhibit treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
PDGF increase
LY294002 PDGF inhibit treatment-induced increase
wortmannin PDGF inhibit treatment-induced increase

S447-p - p70S6K (rat) ▲
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): ‑
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  L6E9
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
LY294002 IGF-1 inhibit treatment-induced increase
wortmannin IGF-1 inhibit treatment-induced increase
insulin increase
LY294002 insulin inhibit treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
PDGF increase
LY294002 PDGF inhibit treatment-induced increase
wortmannin PDGF inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.